Latham & Watkins Advises Intermolecular in Acquisition by Merck KGaA, Darmstadt, Germany

A Silicon Valley-based deal team is leading the US$62 million technology transaction.

May 06, 2019

Intermolecular, Inc. (NASDAQ: IMI) has signed a definitive agreement pursuant to which a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany, a leading science and technology company, will acquire Intermolecular for US$1.20 per share in an all cash transaction, representing an equity value of Intermolecular of approximately US$62 million.

Latham & Watkins LLP represents Intermolecular in the transaction with a corporate deal team led by Silicon Valley partners Tad Freese and Chad Rolston, with associates Bret Stancil, Brad Alvarez, and David Chen. Advice was also provided on technology transactions matters by Silicon Valley partner Anthony Klein, with associates Arielle Singh, Adam Kaldor, and Sophie Cooper; on benefits and compensation matters by Silicon Valley partner James Metz, with associate James Robinson; on tax matters by San Francisco partner Grace Lee, with associate Jessica Chen; and on regulatory matters by Washington, D.C. partner Steven Croley and counsels Scott Jones and Annie Froehlich. 


Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.